Publications by authors named "E Pujol Ribera"
Introduction: The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48 weeks of follow-up. Weight increased with 2DR relative to 3DR but it did not impact on metabolic parameters.
Methods: Multiomics plasma profile was performed to gain further insight into whether this therapy switch might affect specific biological pathways.
Article Synopsis
- The selection of cardiopulmonary bypass (CPB) equipment, specifically the Trilly oxygenator, significantly affects safety and outcomes in pediatric cardiac surgery.
- A study involving 42 pediatric patients demonstrated the Trilly oxygenator's effective performance in gas transfer, maintaining adequate oxygen levels and carbon dioxide removal during surgery.
- Patient demographics showed a mean age of 8 years, with varied underlying conditions, and results indicated that the Trilly oxygenator was both safe and effective for use in this clinical setting.
Introduction: Dolutegravir/rilpivirine (DTG/RPV) is an effective antiretroviral (ART) regimen endorsed by clinical trials as a switch therapy. The aim of our study was to analyse the efficacy and safety of DTG/RPV in real-world clinical practice.
Methods: Observational, multicentre study of patients who started DTG/RPV.
Article Synopsis
- Urgent improvements in crop tolerance to drought are needed due to climate change impacts on agricultural yields.
- Many wild relatives of crops show greater drought tolerance, presenting a potential resource for enhancing crop resilience.
- The study assessed drought responses in eggplant and its wild relatives, revealing that certain hybrids demonstrated superior resistance, which could inform future breeding efforts for improved drought adaptation.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of hydroxychloroquine (HCQ) compared to no treatment in healthcare workers with mild COVID-19.
- Conducted as a prospective, non-randomized study, it included 142 participants—87 received HCQ for five days, while 55 were in the control group.
- Results showed no significant differences in viral load reduction or symptom duration between the groups, and HCQ offered no substantial benefits for health care workers with mild COVID-19.